Spots Global Cancer Trial Database for Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer
Official Title: Prospective, Multicenter, Randomized, Independent-group, Open-label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m2 Body Surface Area as 3-hour Infusion or 22 mg/m2 Body Surface Area as 30-minute or 3-hour Infusion) in Patients With Metastatic Breast Cancer
Study ID: NCT00288249
Study Description
Brief Summary: The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with metastatic breast cancer
Detailed Description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Wien, , Austria
, Wien, , Austria
, Brasschaat, , Belgium
, Plovdiv, , Bulgaria
, Sofia, , Bulgaria
, Varna, , Bulgaria
, Angers, , France
, Bordeaux, , France
, Clermont Ferrand, , France
, Saint Herblain Cedex, , France
, Vandoeuvre les Nancy, , France
, Berlin, , Germany
, Forlì, FC, Italy
, Milano, MI, Italy
, Reggio Emilia, RE, Italy
, Olsztyn, , Poland
, Warszawa, , Poland
, Ljubljana, , Slovenia
, Madrid, , Spain
, Málaga, , Spain
, Manchester, Greater Manchester, United Kingdom
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
